SSD
Clinical safety rating: caution
Comprehensive clinical and safety monograph for SSD (SSD).
Silver sulfadiazine acts by releasing silver ions that bind to microbial DNA and cell membranes, inhibiting bacterial replication and disrupting cell wall synthesis. It also inhibits the folate synthesis pathway via sulfadiazine.
| Metabolism | Hepatic via acetylation (sulfadiazine component); silver is minimally absorbed and excreted in feces |
| Excretion | Renal excretion of unchanged drug (approximately 70-80%) and hepatic metabolism to inactive metabolites (20-30%); less than 2% excreted fecally. |
| Half-life | Terminal half-life: 2-4 hours in adults with normal renal function; clinically, dosing interval is every 6-8 hours due to concentration-dependent bactericidal activity. |
| Protein binding | Binding to serum proteins, primarily albumin: 20-40%. |
| Volume of Distribution | Vd: 0.6-0.8 L/kg, indicating distribution into total body water and binding to tissues; clinically relevant for achieving high tissue concentrations. |
| Bioavailability | Oral: 40-60% due to first-pass metabolism; Topical: minimal systemic absorption (less than 1%) through intact skin but increases to 3-5% through burned or denuded skin. |
| Onset of Action | Oral: 30-60 minutes; Topical: onset of antibacterial effect within 1-2 hours after application. |
| Duration of Action | Duration of antibacterial effect: approximately 6-8 hours after oral administration; topical effect persists for 8-12 hours due to sustained release from cream/ointment base. |
Apply 1/16 inch thick layer to affected area once or twice daily; maintain continuous coverage.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; silver sulfadiazine is minimally absorbed. |
| Liver impairment | No dose adjustment required for hepatic impairment; use with caution in severe hepatic dysfunction due to limited data. |
| Pediatric use | Same as adult dosing; apply 1/16 inch thick layer once or twice daily; avoid use in neonates <2 months due to risk of kernicterus. |
| Geriatric use | Same as adult dosing; monitor for adverse effects due to potential decreased renal function. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for SSD (SSD).
| Breastfeeding | Excretion into breast milk is unknown for topical SSD; systemic absorption is minimal (<1%) but sulfonamides can cause kernicterus in premature or hyperbilirubinemic infants. M/P ratio not established. Caution: avoid use on large areas or for prolonged periods in breastfeeding women. Consider alternative agents. |
| Teratogenic Risk | SSD (silver sulfadiazine) is not recommended for use during pregnancy, especially near term, due to the risk of kernicterus from sulfonamide exposure in the third trimester. FDA Pregnancy Category C: animal studies show adverse effects; no adequate human studies. First trimester: potential for fetal harm based on sulfonamide class effects (e.g., neural tube defects). Second trimester: limited data, avoid unless necessary. Third trimester: contraindicated due to risk of bilirubin displacement and kernicterus in neonates. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to silver sulfadiazine or sulfonamides","Pregnancy at term (near delivery)","Preterm infants or infants <2 months old (risk of kernicterus)","G6PD deficiency (relative)"]
| Precautions | ["Risk of argyria with prolonged use","May cause hemolysis in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency","Renal and hepatic impairment: use with caution","Hypersensitivity reactions","May interfere with wound healing if used on clean, superficial burns"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal renal function and CBC with differential during prolonged therapy. Assess for signs of sulfonamide hypersensitivity. For fetal assessment: consider ultrasound if used in first trimester; monitor neonatal bilirubin levels if used near term. |
| Fertility Effects | No specific human data on fertility effects. Animal studies: no significant reproductive toxicity reported at topical doses. Theoretical risk of spermatotoxicity or ovarian dysfunction from silver absorption is unlikely given minimal systemic absorption. |